Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like Chronic Lower Back pain and Osteoarthritis. Their lead product is a hydrogel for nucleus pulposus augmentation to relieve pain in patients suffering from Chronic Low Back Pain. Gelmetix is a diversified therapeutic biomaterials company incorporated in the UK. It has offices in London, Paris, and Manchester.
Menu
Gelmetix
- Fund: EIS Portfolio Fund
- Sector: Biotech, Medical, Pharma
- Status: Current
- Investment date: October 2019
Our experienced team are here to help. Get in touch today.
General enquiries
01942 271 746
enquiries@senecapartners.co.uk
Investors & advisers
01942 295 985
clientteam@senecapartners.co.uk
Press office
0207 071 3932
zpowell@sharecomms.co.uk
Quick enquiry
Specialists in tax-advantaged investments.
Resources
Copyright © 2022 Seneca Partners Limited. All rights reserved.
Seneca Partners Limited (Company No. 07196273) is Authorised and Regulated by the Financial Conduct Authority (FRN 583361).
Seneca Partners Limited’s registered office is at 9 The Parks, Haydock, WA12 0JQ.